Approved (FDA)

Approved (FDA)

Indicator
IND Enabling
Phase I
Phase II
Phase III
Sickle Cell Disease, SCD, (NCT04819841)
Sponsors:
Graphite Bio Inc
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Renal Cell Carcinoma, RCC, (NCT04696731)
Sponsors:
Allogene Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Acute Myeloid Leukaemia, AML, (NCT04614636)
Sponsors:
Fate Therapeutics, Inc
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-Cell Malignancies, NHL, (NCT04629729)
Sponsors:
Fate Therapeutics
Indicator
IND Enabling
Phase I
Phase II
Phase III
B-cell Non-Hodgkin Lymphoma, NHL, (NCT04637763)
Sponsors:
Caribou Biosciences, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Multiple Myeloma, MM, (NCT04171843)
Sponsors:
Precision BioSciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Non-Hodgkin Lymphoma, NHL, (NCT04030195)
Sponsors:
Precision BioSciences, Inc.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine